Sword Health vs Bristol Myers Squibb
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI digital physical therapy platform. $4B valuation. $240M ARR, cash-flow positive. 2,500+ employers. Founded 2015, Porto/NYC. Raised $340M+. Private.
About
Sword Health is a digital musculoskeletal care company founded in 2015 and headquartered in New York City with engineering roots in Porto, Portugal. The company was founded by physical therapist and engineer Virgílio Bento with the mission of freeing two billion people from pain using AI-powered physical therapy that matches or exceeds the clinical outcomes of in-person care. Sword pioneered the use of sensor-equipped motion trackers combined with AI therapy guidance delivered through a tablet interface.\n\nSword's platform pairs each member with a licensed physical therapist who designs and supervises a personalized program, while an AI engine called Phoenix handles real-time biomechanical coaching during sessions, monitors adherence, and flags clinical concerns for human review. Programs cover the full MSK spectrum — back, neck, shoulder, hip, knee, and post-surgical rehabilitation — as well as pelvic health through its Bloom product. Sword sells to self-insured employers and health plans; it has contracted with more than 2,500 enterprise customers including major Fortune 500 companies.\n\nSword reached $240 million in annualized recurring revenue and achieved cash-flow positivity, a rare milestone among digital health companies at its stage. The company has raised more than $340 million in total funding, reaching a $4 billion valuation. Its clinical evidence base — spanning dozens of peer-reviewed studies demonstrating meaningful pain reduction and return-to-work rates — differentiates Sword in a crowded MSK market and supports its position as the leading AI-native physical therapy platform.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
About
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.